Game-Changing HIV Shot Can’t Get to High-Risk Groups Fast Enough | Lenacapavir proved it's possible to prevent 100% of infections in women. Access and affordability are the next big hurdles.

silence7@slrpnk.net · 5 months ago

Game-Changing HIV Shot Can’t Get to High-Risk Groups Fast Enough | Lenacapavir proved it's possible to prevent 100% of infections in women. Access and affordability are the next big hurdles.

Nurse_Robot@lemmy.world · 5 months ago

Damn, phase 3 double blind randomized study showing 100% effective? That’s huge

partial_accumen@lemmy.world · 5 months ago

“lenacapavir, a twice-yearly shot developed by Gilead Sciences for the prevention of HIV.”

So its not a vaccine, but it would still be incredibly helpful in reducing the spread of of HIV.

mysticpickle@lemmy.ca · 5 months ago

Sadly access and affordability are inversely related to profits and stock price :<

silence7@slrpnk.net · 5 months ago

Historically, the answer on this has involved charging very different amounts in different countries. This both enables some level of access by the poor and maximizes profits.